We are live on ! Find out more
DP

Dearborn Partners Portfolio holdings

AUM $1.85B
1-Year Est. Return 6.59%
This Fund
S&P 500
This Quarter Est. Return
+4.54%
1 Year Est. Return
+6.59%
3 Year Est. Return
+44.33%
5 Year Est. Return
+68.05%
10 Year Est. Return
+241.41%
AUM
$1.15B
AUM Growth
+$77.1M
Cap. Flow
+$32M
Cap. Flow %
2.78%
Top 10 Hldgs %
24.64%
Holding
190
New
8
Increased
98
Reduced
51
Closed
6

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$1.4M
2
CVS icon
CVS Health
CVS
+$1.2M
3
UPS icon
United Parcel Service
UPS
+$1.13M
4
AAPL icon
Apple
AAPL
+$1.05M
5
XLNX
Xilinx Inc
XLNX
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 15.3%
2 Technology 14.52%
3 Industrials 13.42%
4 Consumer Staples 11.59%
5 Consumer Discretionary 6.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EMC
26
DELISTED
EMC CORPORATION
EMC
$17M 1.48%
627,352
+11,605
+2% +$314K
AIZ icon
27
Assurant
AIZ
$14B
$16.6M 1.44%
192,506
+10,276
+6% +$863K
GILD icon
28
Gilead Sciences
GILD
$161B
$16.6M 1.44%
198,661
+15,761
+9% +$1.4M
JKHY icon
29
Jack Henry & Associates
JKHY
$10.9B
$16.3M 1.41%
186,859
+7,486
+4% +$626K
TRV icon
30
Travelers Companies
TRV
$79B
$16.1M 1.4%
135,423
+8,692
+7% +$983K
RTX icon
31
RTX Corp
RTX
$290B
$16.1M 1.4%
249,139
+6,523
+3% +$417K
APD icon
32
Air Products & Chemicals
APD
$65.4B
$15.2M 1.32%
115,389
+4,187
+4% +$558K
ITC
33
DELISTED
ITC HOLDINGS CORP
ITC
$15M 1.3%
319,381
+16,187
+5% +$718K
CVS icon
34
CVS Health
CVS
$134B
$14.7M 1.28%
153,827
+12,068
+9% +$1.2M
MRK icon
35
Merck
MRK
$323B
$14.7M 1.27%
267,021
+8,611
+3% +$458K
NEE icon
36
NextEra Energy
NEE
$183B
$14M 1.22%
430,800
-5,388
-1% -$162K
XLNX
37
DELISTED
Xilinx Inc
XLNX
$14M 1.22%
303,598
+22,877
+8% +$1.05M
CBSH icon
38
Commerce Bancshares
CBSH
$8.57B
$13.8M 1.2%
469,487
+15,719
+3% +$453K
BR icon
39
Broadridge
BR
$17.8B
$12.8M 1.11%
196,047
+10,904
+6% +$676K
ACN icon
40
Accenture
ACN
$100B
$12.7M 1.1%
112,016
+6,002
+6% +$696K
IFF icon
41
International Flavors & Fragrances
IFF
$20.2B
$12.2M 1.06%
96,646
+5,777
+6% +$714K
UNP icon
42
Union Pacific
UNP
$174B
$12.1M 1.05%
139,032
+7,608
+6% +$643K
BCR
43
DELISTED
CR Bard Inc.
BCR
$11.6M 1.01%
49,270
-525
-1% -$114K
WBA
44
DELISTED
Walgreens Boots Alliance
WBA
$11.4M 0.99%
137,407
+6,568
+5% +$530K
LEG icon
45
Leggett & Platt
LEG
$1.36B
$11.3M 0.98%
221,292
+12,742
+6% +$627K
ROST icon
46
Ross Stores
ROST
$80.9B
$10.8M 0.94%
190,612
+9,909
+5% +$550K
OXY icon
47
Occidental Petroleum
OXY
$55.9B
$10.7M 0.93%
141,642
+7,547
+6% +$564K
VZ icon
48
Verizon
VZ
$194B
$10.5M 0.91%
188,391
-908
-0.5% -$47.1K
DLR icon
49
Digital Realty Trust
DLR
$70.7B
$9.72M 0.84%
89,181
-666
-0.7% -$63.2K
MSFT icon
50
Microsoft
MSFT
$3.44T
$9.45M 0.82%
184,662
-1,100
-0.6% -$57.2K

Similar funds

Dearborn Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Dearborn Partners held 190 positions worth $1.15B, up 7.2% from $1.08B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Dearborn Partners's Q2 2016 filing shows 8 new, 98 increased, 51 reduced and 6 closed positions. Its largest new stake was Vanguard FTSE Emerging Markets ETF: 15,191 shares worth $535K. The largest sale was Vanguard Morningstar Mega Cap Growth ETF, an estimated $823K.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 15% a quarter earlier, followed by Technology and Industrials.

  • Dearborn Partners's largest Q2 2016 buy was Vanguard FTSE Emerging Markets ETF: 15,191 shares worth $535K.
  • Dearborn Partners added most to Gilead Sciences in Q2 2016, an estimated $1.4M increase.
  • Dearborn Partners's biggest Q2 2016 reduction was Vanguard Morningstar Mega Cap Growth ETF, cutting an estimated $823K.
  • Dearborn Partners fully exited iShares Currency Hedged MSCI EAFE ETF in Q2 2016, selling an estimated $372K.
  • Dearborn Partners's ten largest holdings make up 25% of its $1.15B portfolio in Q2 2016.
  • Dearborn Partners opened 8 new positions and closed 6 in Q2 2016.
  • Dearborn Partners's portfolio value rose 7.2% quarter-over-quarter to $1.15B.

Based on Dearborn Partners's 13F filing for Q2 2016, filed 18 Jul 2016.